Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 12/20 | 0.77 |
| ▸ | CCR2 | P41597 | 9/20 | 0.77 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.77 |
| ▸ | CCR7 | P32248 | 2/20 | 0.77 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL17555091 | 0.99 | CCR5 (0.78) | CCR5CCR2CXCR3CCR7CXCR5 | |
| Hydrochloric Acid SCHEMBL2900185 | 0.99 | CCR5 (0.78) | CCR5CCR2CXCR3CCR7CXCR5 | |
| SCHEMBL13148344 | 0.92 | CCR5 (0.65) | CCR5CCR2CXCR3CCR7CXCR5 | |
| Hydrochloric Acid SCHEMBL313839 | 0.91 | CCR5 (0.66) | CCR5CCR2CXCR3CCR7CXCR5 | |
| Iodide SCHEMBL17555111 | 0.91 | CCR5 (0.66) | CCR5CCR2CXCR3CCR7CXCR5 | |
| SCHEMBL13148343 | 0.90 | CCR5 (0.62) | CCR5CCR2CXCR3CCR7CXCR5 | |
| Hydrochloric Acid SCHEMBL313749 | 0.89 | CCR5 (0.63) | CCR5CCR2CXCR3CCR7CXCR5 | |
| SCHEMBL2695971 | 0.87 | CXCR3 (0.78) | CCR5CCR2CXCR3CCR7CXCR5 | |
| SCHEMBL30241629 | 0.87 | CCR5 (1.00) | CCR5CCR2CXCR3CCR7CXCR5 | |
| SCHEMBL1161322 | 0.87 | CCR5 (1.00) | CCR5CCR2CXCR3CCR7CXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765803-B1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-8168829-B2 | Synthesis of quaternary salt compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-01 | — | — | US | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090112004-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090112004-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | CCR2, CCR1, CCL11 | CCR5 7/4885CCR2 1/4885CXCR3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.